OmniAb, Inc.

OABI

$4.75

-5.75%

N/A-$0.29

Healthcare

Biotechnology

NASDAQ

Active Trading

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its ...

CEO Profile of OABI

Matthew W. Foehr

OmniAb, Inc.

Age 53Tenure 4yKey-man risk: Medium

Matthew Foehr has successfully navigated OmniAb's transition to an independent, publicly traded entity. While the business model remains highly volatile due to milestone-based revenue, his operational experience and focus on...

Key Risk

•Dependency on unpredictable milestone payments.

•High competition in antibody discovery services.

•Operating losses.

Key Tailwind

•Strong and growing partner ecosystem.

•Proven discovery platform technology.

•Stable leadership with long-term industry expertise.

Matthew W. Foehr

OmniAb, Inc. (OABI) · NASDAQ

Age 53Tenure 4 yearsNon-founder CEOKey-man risk: Medium

matthew-foehr

Origin Story

An industry veteran with 25+ years of pharmaceutical experience, Foehr transitioned from leadership at Ligand Pharmaceuticals to become the inaugural CEO of the newly independent OmniAb in 2022.

First Break: Career began at Ernst & Young LLP supporting private and public biotechnology and software companies.

Path to CEO: Prior to joining OmniAb, Foehr served as President and Chief Operating Officer at Ligand Pharmaceuticals, where he played a central role in the company's technology development and business strategy. Following the spin-off of OmniAb, he took the helm to lead the company as an independent entity, focusing on platform licensing and R&D partnerships.

Matthew Foehr is an experienced biopharma executive who spent decades building expertise in R&D and operations before taking the CEO role at OmniAb. He was instrumental in managing the transition of OmniAb from a business unit of Ligand into a standalone public company. His tenure is characterized by a drive to expand the partner network and demonstrate the value of proprietary discovery platforms.

biopharma executiveindustry veteran

Investment Take

Key Tailwinds

Strong and growing partner ecosystem.

Proven discovery platform technology.

Stable leadership with long-term industry expertise.

Key Risks

Dependency on unpredictable milestone payments.

High competition in antibody discovery services.

Operating losses.

Career History

A long-standing career in the pharmaceutical and biotechnology sectors, primarily focused on operations and technology development.

OmniAb, Inc.

Initiative: President and CEO

Period: 2022–Present

Event: Led the company as an independent entity, expanded the number of partner license agreements.

Ligand Pharmaceuticals

Initiative: President and Chief Operating Officer

Event: Managed technology development and global research and development programs.

Ernst & Young LLP

Initiative: Professional

Period: Early Career

Event: Supported private and public biotechnology and software companies.

pharmaceutical operationsbiotech

Company Performance

Performance is highly volatile, dependent on milestone revenue, with the company currently working to build consistent long-term licensing momentum.

Revenue: Highly fluctuating; 2025 revenue of $18.7M vs $26.4M in 2024; Q1 2026 revenue showed a sharp increase to $14.4M from $4.2M in Q1 2025 due to milestone timing.

Profitability: Currently operating at a loss; 2025 net loss of approximately $64.78M.

Stock: Has faced significant market pressure as a spin-off; YTD 2026 return as of July is approximately 17%.

•Increased number of platform license agreements to over 80 partners.

•Revenue variability due to milestone payment timing.

•Ongoing operating losses.

volatile revenuepre-profitablemilestone dependency

Management Ability

Foehr is viewed as an operational leader focusing on partner growth and strategic alignment.

Style: Hands-on operational leader

Foehr emphasizes expanding the partner ecosystem and licensing the company's antibody discovery platforms. He maintains active engagement with investors through regular earnings calls and industry conferences, clearly outlining the firm's strategic focus. He has built a management team tasked with stabilizing the standalone entity's operations and financial reporting.

operational focuspartner-centric

Capital Allocation

Capital allocation is centered on maintaining platform R&D and managing cash to extend the runway while seeking milestone-heavy licensing deals.

High level of scrutiny on operating expenses; CEO has participated in insider share purchases, signaling confidence.

As a pre-profitable company, OmniAb focuses heavily on capital conservation while balancing necessary investment in their discovery platforms. The company's cost management is a key focus for Foehr, as they navigate periods of inconsistent cash inflows from licensing milestones. Insider buying by Foehr suggests he remains committed to internal alignment with shareholders.

cost-consciousinsider buying

Fundraising & Financing

The company operates with a focus on milestone-driven revenue and disciplined cost management rather than aggressive equity dilution.

Dilution: minimal

Financing philosophy is rooted in managing the company's cash reserves from its spin-off. Foehr's focus remains on licensing milestones to sustain operations without relying heavily on dilutive financing. Investor confidence remains linked to the success of the platform in generating new, high-value partnerships.

cash discipline

Governance & Control

Maintains standard governance structure as a public company following its independence.

Governance is typical of mid-cap biotech companies. Foehr is the only employee on the Board of Directors, ensuring independent board oversight. Shareholders have consistently relied on standard public company governance practices.

board oversight

Health & Succession

No public concerns or specific disclosures regarding health or succession risk.

Health Status: no public concerns

Key-man Risk: Medium

no concerns

R&D & Tech Vision

Focuses on maintaining the competitiveness of proprietary antibody discovery platforms, which is the core value driver of the business.

Sustained investment as a core component of the business model.

High focus on platform evolution.

The vision is to continuously enhance and innovate the discovery platform to ensure it remains essential to pharmaceutical partners. R&D spend is targeted to maximize the output of antibody candidates, which translates into licensing and milestone opportunities for the firm.

innovation drivenr&d focus

Talent Recruitment

Strong focus on hiring technical and business development talent to support partnership growth.

Functional and experienced in biotech operations.

Retention: strong

Foehr has assembled a team capable of managing the complexities of a platform licensing business. The culture is driven by the need for operational excellence and deep scientific capability, attracting personnel with long histories in the industry.

experienced team

Strengths

Strong operational and technical experience combined with deep biopharma sector relationships.

Industry experience: More than 25 years of pharmaceutical industry leadership.

sector expertise

Weaknesses & Failures

Susceptibility to revenue volatility inherent in a milestone-based business model.

Revenue predictability

Financial performance is highly dependent on the timing and occurrence of partner milestones.

Example: Year-over-year revenue volatility in 2025 vs 2024.

revenue volatility

Marketing & Brand

Brand strategy focuses on cementing OmniAb as the go-to discovery platform partner for global biopharma companies.

Focused on establishing brand authority through partnership volume.

Marketing efforts are primarily B2B, centered on industry conferences and strategic collaborations. Foehr is the public face of the brand, emphasizing the breadth and success of their licensing business to demonstrate market adoption of their proprietary discovery technologies.

b2b marketingpartnership brand

PR & Communication

Professional and transparent communicator, maintaining regular contact with the investment community.

Media Reputation: positive

Foehr is articulate in earnings calls, focusing on clear explanations of milestone-based revenue and the long-term utility of the OmniAb platform. His media presence is professional and restricted largely to industry events and financial interviews. He successfully manages investor expectations despite the inherent volatility of the company's financial model.

transparentprofessional

Supply Chain of OABI

Upstream / Downstream / Proxies

Upstream

GenScript Biotech CorporationHKEx:1548 Ligand Pharmaceuticals IncorporatedNASDAQ:LGNDContract Research Organization Network (US, Europe, Asia)Laboratory Animal Breeding & Production FacilitiesThermo Fisher Scientific Inc.NYSE:TMO Illumina, Inc.NASDAQ:ILMN 10x Genomics, Inc.NASDAQ:TXG Bio-Rad Laboratories, Inc.NYSE:BIO Danaher Corporation (Cytiva)NYSE:DHR Charles River Laboratories International, Inc.NYSE:CRL Revvity, Inc. (f/k/a PerkinElmer) — BioLegendNYSE:RVTY

Downstream

Janssen Pharmaceuticals (Johnson & Johnson)NYSE:JNJTakeda Pharmaceutical Company LimitedTSE:4502Gilead Sciences, Inc.NASDAQ:GILD Sanofi S.A.NASDAQ:SNYServierBaxter International Inc.NYSE:BAX Amgen Inc.NASDAQ:AMGN Merck & Co., Inc.NYSE:MRK Pfizer Inc.NYSE:PFE AbbVie Inc.NYSE:ABBVRoche Holding AG (Genentech)SWX:ROGBristol Myers Squibb CompanyNYSE:BMYNovartis AGSWX:NOVNDana-Farber Cancer InstituteMabtrx BiosciencesWyss Institute for Biologically Inspired Engineering (Harvard University)ArrowMark Partners / Viking Global Investors (NewCo)GenScript Biotech CorporationHKEx:1548

Proxies

AbCellera Biologics Inc.NASDAQ:ABCL Regeneron Pharmaceuticals, Inc.NASDAQ:REGN Ligand Pharmaceuticals IncorporatedNASDAQ:LGND Genmab A/SNASDAQ:GMAB

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer